Cited by 195Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

Open access
Vemuri, Prashanthi, Wiste, Heather J., Weigand, Stephen D., Knopman, David S., Shaw, Leslie M., Trojanowski, John Q., Aisen, Paul S., Weiner, Michael +3 more·2010·Annals of Neurology

Abstract

Objective: To study the effect of apolipoprotein E ϵ4 status on biomarkers of neurodegeneration (atrophy on magnetic resonance imaging [MRI]), neuronal injury (cerebrospinal fluid [CSF] t‐tau), and brain Aβ amyloid load (CSF Aβ 1–42) in cognitively normal subjects (CN), amnestic subjects with mild cognitive impairment (aMCI), and patients with Alzheimer disease (AD). Methods: We included all 399 subjects (109 CN, 192 aMCI, 98 AD) from the Alzheimer's Disease Neuroimaging Initiative study with baseline CSF and MRI scans. Structural Abnormality Index (STAND) scores, which reflect the degree of AD‐like anatomic features on MRI, were computed for each subject. Results: A clear ϵ4 allele dose effect was seen on CSF Aβ 1–42 levels within each clinical group. In addition, the proportion of the variability in Aβ 1–42 levels explained by APOE ϵ4 dose was significantly greater than the proportion of the variability explained by clinical diagnosis. On the other hand, the proportion of the variability in CSF t‐tau and MRI atrophy explained by clinical diagnosis was greater than the proportion of the variability explained by APOE ϵ4 dose; however, this effect was only significant for STAND scores. Interpretation: Low CSF Aβ 1–42 (surrogate for Aβ amyloid load) is more closely linked to the presence of APOE ϵ4 than to clinical status. In contrast, MRI atrophy (surrogate for neurodegeneration) is closely linked with cognitive impairment, whereas its association with APOE ϵ4 is weaker. The data in this paper support a model of AD in which CSF Aβ 1–42 is the earliest of the 3 biomarkers examined to become abnormal in both APOE carriers and noncarriers. ANN NEUROL 2010;67:308–316

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.21953

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE4 carriers feature decreased cortical thickness and smaller hippocampal volume, and advanced MCI age compared to non-carriers.

    “Studies showed that APOE4 carriers featured decreased cortical thickness and smaller hippocampal volume, and with an advanced mild cognitive impairment (MCI) age compared to non-carriers [462–464].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., & Initiative, A. D. N.
Affiliations
  • Mayo Clinic (US)
  • University of Pennsylvania (US)
  • University of California San Diego (US)
  • San Francisco VA Medical Center (US)
  • Alzheimer’s Disease Neuroimaging Initiative (US)
Corresponding author
Jack, Clifford R.
Venue
Annals of Neurology
Publisher
Wiley
Published
2010-03
Volume
67
Issue
3
Pages
308-316
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1484611135
Cited by
195
References
61
Citations by year
2026: 5 · 2025: 8 · 2024: 6 · 2023: 3 · 2022: 9 · 2021: 10 · 2020: 13 · 2019: 5 · 2018: 8 · 2017: 12 · 2016: 12 · 2015: 21 · 2014: 8 · 2013: 25 · 2012: 13
FWCI
10.28
Type
journal article
Language
en
Open access
Locations
  • Annals of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5u01ag024904-10)
  • National Institute on Aging (U01-AG-024904, R01AG011378, AG-11378, U19AG010483, R37AG011378)
  • National Center for Research Resources (RR018898, C06RR018898)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
APOE ε4, Alzheimer's disease, amyloid-beta 42, cerebrospinal fluid biomarkers, tau protein, neurodegeneration, brain atrophy, mild cognitive impairment, amyloid load, neuronal injury
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Atrophy, Brain, DNA Mutational Analysis, Female, Genetic Markers, Genetic Testing, Genotype, Humans, Magnetic Resonance Imaging, Male, Peptide Fragments, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Apolipoprotein E4, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review